TScan Therapeutics (NASDAQ:TCRX) is a clinical-stage biotechnology company focused on the discovery and development of T cell receptor (TCR)-based immunotherapies for cancer. Leveraging its proprietary T-Scan® platform, the company identifies and validates tumor-specific antigens presented on the surface of cancer cells. By coupling high-throughput screening with advanced computational analytics, TScan aims to develop next-generation TCR therapies capable of targeting a broad array of solid tumor indications with precision and durability.
The company’s lead pipeline candidates include autologous and allogeneic TCR-engineered T cell programs directed at well-validated cancer antigens. Preclinical data have demonstrated potent and selective cytotoxic activity against tumor cell lines, paving the way for planned IND submissions and early-phase clinical trials. TScan is also exploring multiplex engineering approaches to enhance T cell persistence, safety and tumor infiltration, positioning its portfolio for potential differentiation in a competitive immuno-oncology landscape.
Founded in 2018 and headquartered in Cambridge, Massachusetts, TScan emerged from pioneering research at leading academic institutions. The company completed a public listing on the Nasdaq exchange in August 2021 under the ticker TCRX, raising capital to advance its discovery engine and clinical pipeline. Under the leadership of President and Chief Executive Officer James J. Mastrianni, Ph.D., and Chief Scientific Officer Marcela Varela, Ph.D., TScan has assembled a multidisciplinary team of immunologists, molecular biologists and translational scientists.
In addition to its internal programs, TScan has forged research collaborations and strategic partnerships to broaden the application of its TCR platform across multiple cancer types. While its primary operations are in the United States, the company is actively exploring global development plans and regulatory pathways to extend the reach of its immuno-oncology innovations to patients worldwide.
